
Gilead signs royalty-free licensing agreements with three generic manufacturers to expand future access to its investigational antiviral obeldesivir.
March 01, 2017
A new report reveals the orphan drug market has grown at approximately double the overall growth of the prescription market.
Highlights of the
The “EvaluatePharma Orphan Drug Report 2017” can be downloaded at:






